Scholarlink

Objective <p>Percutaneous cryoablation (PC) has been incorporated among first-line treatment options for desmoid-type fibromatosis (DF). Loco-regional therapies, including PC, induce tissue changes that may precede measurable tumor shrinkage, thereby limiting the reliability of purely dimensional response criteria. To address this limitation, we compared response evaluation criteria in solid tumors (RECIST) 1.1 and magnetic resonance imaging (MRI)-adapted (M-)RECIST in patients with DF treated with PC.</p> Materials and methods <p>We retrospectively identified all consecutive patients with progressing extra-abdominal DF treated with PC. Responses were assessed with RECIST 1.1 and M-RECIST, the latter relying on T2- and diffusion-weighted imaging, as well as unenhanced and contrast-enhanced T1-weighted imaging, to define residual viable tumor. Non-progression (NPR) and overall response rates (ORR) were defined as the percentage of patients without radiological progression and partial/complete responses, respectively.</p> Results <p>Thirty-four patients (females/males, 26/8) and 37 procedures were identified. RECIST 1.1 and M-RECIST were applicable in 35 and 34 procedures, respectively. At a median follow-up of 15.7 months (interquartile range [IQR] 19.5), RECIST 1.1. Responses were: 10/35 (28.6%) partial response (PR), 22/35 (62.9%) stable disease (SD), and 3/35 (8.6%) progressive disease (PD), with ORR 28.6% and NPR 91.4%. At a median follow-up of 16.0 months (IQR 20.5), M-RECIST responses were: 15/34 (44.1%) complete response (CR), 12/34 (35.3%) PR, 4/34 (11.8%) SD, and 3/34 (8.8%) PD, with ORR 79.4% and NPR 91.2%. Overall concordance was negligible.</p> Conclusion <p>M-RECIST yielded higher NPR/ORR than RECIST 1.1. These findings pave the way for studies addressing whether this shift in response categorization associates with improved outcomes prediction.</p> Relevance statement <p>This work provides supporting evidence for the implementation of residual viable disease assessment in evaluating DF responses to PC.</p> Key Points <p><UnorderedList Mark="Bullet"> <ItemContent> <p>In patients with DF, responses to cryoablation can be characterized using purely dimensional and viability-based criteria.</p> </ItemContent> <ItemContent> <p>RECIST 1.1 and M-RECIST yielded complete agreement for PD.</p> </ItemContent> <ItemContent> <p>M-RECIST may refine response categorization below the progression threshold.</p> </ItemContent> </UnorderedList></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Andrea Vanzulli,
  • Lorenzo Saggiante,
  • Lucilla Violetta Sciacqua,
  • Tommaso Cascella,
  • Carlo Spreafico,
  • Giorgio Greco,
  • Rodolfo Lanocita,
  • Emanuele Rausa,
  • Marco Vitellaro,
  • Gabriele Tiné,
  • Elena Palassini,
  • Rosalba Miceli,
  • Sandro Pasquali,
  • Marco Fiore,
  • Paolo Giovanni Casali,
  • Silvia Stacchiotti,
  • Alessandro Gronchi,
  • Chiara Colombo,
  • Carlo Morosi

摘要

Objective

Percutaneous cryoablation (PC) has been incorporated among first-line treatment options for desmoid-type fibromatosis (DF). Loco-regional therapies, including PC, induce tissue changes that may precede measurable tumor shrinkage, thereby limiting the reliability of purely dimensional response criteria. To address this limitation, we compared response evaluation criteria in solid tumors (RECIST) 1.1 and magnetic resonance imaging (MRI)-adapted (M-)RECIST in patients with DF treated with PC.

Materials and methods

We retrospectively identified all consecutive patients with progressing extra-abdominal DF treated with PC. Responses were assessed with RECIST 1.1 and M-RECIST, the latter relying on T2- and diffusion-weighted imaging, as well as unenhanced and contrast-enhanced T1-weighted imaging, to define residual viable tumor. Non-progression (NPR) and overall response rates (ORR) were defined as the percentage of patients without radiological progression and partial/complete responses, respectively.

Results

Thirty-four patients (females/males, 26/8) and 37 procedures were identified. RECIST 1.1 and M-RECIST were applicable in 35 and 34 procedures, respectively. At a median follow-up of 15.7 months (interquartile range [IQR] 19.5), RECIST 1.1. Responses were: 10/35 (28.6%) partial response (PR), 22/35 (62.9%) stable disease (SD), and 3/35 (8.6%) progressive disease (PD), with ORR 28.6% and NPR 91.4%. At a median follow-up of 16.0 months (IQR 20.5), M-RECIST responses were: 15/34 (44.1%) complete response (CR), 12/34 (35.3%) PR, 4/34 (11.8%) SD, and 3/34 (8.8%) PD, with ORR 79.4% and NPR 91.2%. Overall concordance was negligible.

Conclusion

M-RECIST yielded higher NPR/ORR than RECIST 1.1. These findings pave the way for studies addressing whether this shift in response categorization associates with improved outcomes prediction.

Relevance statement

This work provides supporting evidence for the implementation of residual viable disease assessment in evaluating DF responses to PC.

Key Points

In patients with DF, responses to cryoablation can be characterized using purely dimensional and viability-based criteria.

RECIST 1.1 and M-RECIST yielded complete agreement for PD.

M-RECIST may refine response categorization below the progression threshold.

Graphical Abstract